OncoPep is developing PVX-410, an investigational cancer vaccine designed to stop disease progression in multiple myeloma. In addition to smoldering multiple myeloma (SMM), our investigational peptide portfolio more broadly targets multiple myeloma, triple negative breast cancer (TNBC) and several s
Employees: 11-50
Total raised: $6.9M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Cobro Vent... | cobroventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.08.2014 | Series B | $6.9M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.12.2021 | OncoPep Pulls In $11M Series D Round | CAMBRIDGE, MA, OncoPep, a developer of transformative immunotherapeutics, announced $11 million in Series D funding. >> Click here for more funding data on OncoPep >> To export OncoPep funding data to PDF and Excel, click he... |
| 28.08.2014 | OncoPep Raises $6.9M in Series B | BOSTON, MA, OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. >> Click here for more funding data on OncoPep >> To export OncoPep funding data to PDF and Excel,... |
| 28.08.2014 | OncoPep Closes $6.9M Series B Financing | OncoPep, Inc., a Boston, MA-based developer of targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients, closed a $6.9m Series B financing. Backers included angel groups,... |